Sughrue Nature Article Indicates Supreme Court Broadens Patenting of Biotech Processes

With over 60 biopharmaceutical products applied for or expected to be filed at the US Food and Drug Administration this year, joining over 335 currently approved biopharmaceuticals, determining what can or cannot be patented is a threshold question protecting inventions in biotech and pharmaceutical industry. The Supreme Court has made the answer to this question much clearer in deciding Bilski v. Kappos.